Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P; GFM (Groupe Francophone des Myélodysplasies). Rose C, et al. Among authors: cheze s. Leuk Res. 2010 Jul;34(7):864-70. doi: 10.1016/j.leukres.2009.12.004. Epub 2010 Feb 2. Leuk Res. 2010. PMID: 20129667
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L, Park S, Vaultier S, Hamza F, Beyne-rauzy MO, Cheze S, Giraudier S, Agape P, Legros L, Voillat L, Dreyfus F, Fenaux P; Groupe Francais des Myelodysplasies. Mannone L, et al. Among authors: cheze s. Br J Haematol. 2006 Jun;133(5):513-9. doi: 10.1111/j.1365-2141.2006.06070.x. Br J Haematol. 2006. PMID: 16681638 Free article. Clinical Trial.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.
Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F; GFM group (Groupe Francophone des Myélodysplasies). Park S, et al. Among authors: cheze s. Blood. 2008 Jan 15;111(2):574-82. doi: 10.1182/blood-2007-06-096370. Epub 2007 Oct 16. Blood. 2008. PMID: 17940203 Free article. Clinical Trial.
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
Itzykson R, Ayari S, Vassilief D, Berger E, Slama B, Vey N, Suarez F, Beyne-Rauzy O, Guerci A, Cheze S, Thomas X, Stamatoullas A, Gardembas M, Bauduer F, Kolb A, Chaury MC, Legros L, Damaj G, Chermat F, Dreyfus F, Fenaux P, Ades L; Groupe Francophone des Myelodysplasies (GFM). Itzykson R, et al. Among authors: cheze s. Leukemia. 2009 Apr;23(4):673-8. doi: 10.1038/leu.2008.362. Epub 2009 Jan 8. Leukemia. 2009. PMID: 19151787 Clinical Trial.
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Kelaidi C, Stamatoullas A, Beyne-Rauzy O, Raffoux E, Quesnel B, Guerci A, Dreyfus F, Brechignac S, Berthou C, Prebet T, Hicheri Y, Hacini M, Delaunay J, Gourin MP, Camo JM, Zerazhi H, Taksin AL, Legros L, Choufi B, Fenaux P; Groupe Francophone des Myélodysplasies. Kelaidi C, et al. Haematologica. 2010 Jun;95(6):892-9. doi: 10.3324/haematol.2009.014357. Epub 2009 Dec 16. Haematologica. 2010. PMID: 20015890 Free PMC article.
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F. Park S, et al. Among authors: cheze s. Leuk Res. 2010 Nov;34(11):1430-6. doi: 10.1016/j.leukres.2010.05.030. Epub 2010 Jun 26. Leuk Res. 2010. PMID: 20580086
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Porter JB, et al. Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29. Eur J Haematol. 2011. PMID: 21649735 Free PMC article. Clinical Trial.
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Amé S, Tertian G, Slama B, Fenaux P, Dreyfus F. Park S, et al. Among authors: cheze s. Leuk Res. 2011 Nov;35(11):1530-3. doi: 10.1016/j.leukres.2011.07.007. Epub 2011 Jul 30. Leuk Res. 2011. PMID: 21803419
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies. Damm F, et al. Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17. Blood. 2012. PMID: 22343920 Free article.
88 results